Rapid antifungal susceptibility determination for yeast isolates by use of Etest performed directly on blood samples from patients with fungemia

Journal of Clinical Microbiology

Volumn 48, Issue 6, 2010, Pages 2205-2212

  Guinea, Jesús ^a,b,c   Recio, Sandra ^a   Escribano, Pilar ^a   Torres Narbona, Marta ^a   Peláez, Teresa ^a,b,c   Sánchez Carrillo, Carlos ^a,b   Rodríguez Créixems, Marta ^a,b,c   Bouza, Emilio ^a,b,c  

^a HOSPITAL GENERAL UNIVERSITARIO GREGORIO MARAÑÓN   (Spain)

^b INSTITUTO DE SALUD CARLOS III   (Spain)

^c SCHOOL OF MEDICINE   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

AMPHOTERICIN B; CASPOFUNGIN; FLUCONAZOLE; ISAVUCONAZOLE; POSACONAZOLE; VORICONAZOLE;

ANTIFUNGAL ACTIVITY; ANTIFUNGAL RESISTANCE; ANTIFUNGAL SUSCEPTIBILITY; ARTICLE; ARXULA ADENINIVORANS; BLOOD SAMPLING; BROTH DILUTION; CANDIDA; CANDIDA ALBICANS; CANDIDA DUBLINIENSIS; CANDIDA GLABRATA; CANDIDA KRUSEI; CANDIDA PARAPSILOSIS; CANDIDA TROPICALIS; CONTROLLED STUDY; CRYPTOCOCCUS NEOFORMANS; EPSILOMETER TEST; FUNGAL STRAIN; FUNGEMIA; FUNGUS ISOLATION; GRAM STAINING; HUMAN; INCUBATION TIME; KLUYVEROMYCES MARXIANUS; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PICHIA GUILLIERMONDII; PRIORITY JOURNAL; RHODOTORULA MUCILAGINOSA; SACCHAROMYCES CEREVISIAE; TRICHOSPORON INKIN; TRICHOSPORON MUCOIDES; YEAST;

ANTIFUNGAL AGENTS; DIAGNOSTIC ERRORS; FUNGEMIA; HUMANS; MICROBIAL SENSITIVITY TESTS; YEASTS;

CANDIDA; CANDIDA GLABRATA; CANDIDA TROPICALIS;

EID: 77952934638     PISSN: 00951137     EISSN: None     Source Type: Journal    
DOI: 10.1128/JCM.02321-09     Document Type: Article

References (29)

1. Almirante, B., D. Rodríguez, B. J. Park, M. Cuenca-Estrella, A. M. Planes, M. Almela, J. Mensa, F. Sánchez, J. Ayats, M. Giménez, P. Saballs, S. K. Fridkin, J. Morgan, J. L. Rodríguez-Tudela, D. W. Warnock, and A. Pahissa. 2005. Epidemiology and predictors of mortality in cases of Candida blood-stream infection: results from population-based surveillance, Barcelona, Spain, from 2002 to 2003. J. Clin. Microbiol. 43:1829-1835.
2. Armstrong-James, D. 2007. Invasive Candida species infection: the importance of adequate empirical antifungal therapy. J. Antimicrob. Chemother. 60:459-460.
3. Arthington-Skaggs, B. A., W. Lee-Yang, M. A. Ciblak, J. P. Frade, M. E. Brandt, R. A. Hajjeh, L. H. Harrison, A. N. Sofair, and D. W. Warnock. 2002. Comparison of visual and spectrophotometric methods of broth microdilution MIC endpoint determination and evaluation of a sterol quantitation method for in vitro susceptibility testing of fluconazole and itraconazole against trailing and nontrailing Candida isolates. Antimicrob. Agents Chemother. 46:2477-2481.
4. Bouza, E., M. V. Torres, C. Radice, E. Cercenado, R. de Diego, C. Sánchez-Carrillo, and P. Muñoz. 2007. Direct E-test (AB Biodisk) of respiratory samples improves antimicrobial use in ventilator-associated pneumonia. Clin. Infect. Dis. 44(3):382-387.
5. Cercenado, E., S. Cercenado, M. Marín, M. V. Rico, T. Vicente, and E. Bouza. 2007. Evaluation of direct E-test on lower respiratory tract samples: a rapid and accurate procedure for antimicrobial susceptibility testing. Diagn. Microbiol. Infect. Dis. 58:211-216.
6. Chang, H. C., J. J. Chang, S. H. Chan, A. H. Huang, T. L. Wu, M. C. Lin, and T. C. Chang. 2001. Evaluation of Etest for direct antifungal susceptibility testing of yeasts in positive blood cultures. J. Clin. Microbiol. 39:1328-1333.
7. Clinical and Laboratory Standards Institute. 2008. Reference method for broth dilution antifungal susceptibility testing of yeasts. Approved standard CLSI document M27-A3. Clinical and Laboratory Standards Institute, Wayne, PA.
8. Espinel-Ingroff, A., E. Cantón, J. Pemán, M. G. Rinaldi, and A. W. Fothergill. 2009. Comparison of 24-hour and 48-hour voriconazole MICs as determined by the Clinical and Laboratory Standards Institute broth microdilution method (M27-A3 document) in three laboratories: results obtained with 2,162 clinical isolates of Candida spp. and other yeasts. J. Clin. Microbiol. 47:2766-2771.
9. Espinel-Ingroff, A., L. Steele-Moore, and J. N. Galgiani. 1994. Evaluation of 80% inhibition standards for the determination of fluconazole minimum inhibitory concentrations in three laboratories. Diagn. Microbiol. Infect. Dis. 20:81-86.
10. Food and Drug Administration. 2003. Class II special controls guidance document: antimicrobial susceptibility testing systems: guidance for industry. Food and Drug Administration, Washington, DC.
11. Garey, K. W., M. Rege, M. P. Pai, D. E. Mingo, K. J. Suda, R. S. Turpin, and D. T. Bearden. 2006. Time to initiation of fluconazole therapy impacts mortality in patients with candidemia: a multi-institutional study. Clin. Infect. Dis. 43:25-31.
12. Guinea, J., and E. Bouza. 2008. Isavuconazole: a new and promising anti-fungal triazole for the treatment of invasive fungal infections. Future Microbiol. 3:603-615.
13. Guinea, J., T. Peláez, S. Recio, M. Torres-Narbona, and E. Bouza. 2008. In vitro antifungal activities of isavuconazole (BAL4815), voriconazole, and fluconazole against 1,007 isolates of Zygomycete, Candida, Aspergillus, Fusarium, and Scedosporium species. Antimicrob. Agents Chemother. 52:1396-1400.
14. Guinea, J., S. Recio, P. Escribano, T. Peláez, M. Torres-Narbona, M. Rodríguez-Créixems, C. Sánchez-Carrillo, and E. Bouza. 2010. Antifungal susceptibility of yeasts isolated from patients with fungaemia: comparison of the E-test on direct blood samples and CLSI M27-A3. Abstr. 20th Conf. Eur. Congr. Clin. Microbiol. Infect. Dis., Vienna, Austria, abstr. P-838.
15. Krcmery, V., and A. J. Barnes. 2002. Non-albicans Candida spp. causing fungaemia: pathogenicity and antifungal resistance. J. Hosp. Infect. 50:243-260.
16. Lagrou, K., J. Verhaegen, W. E. Peetermans, T. De Rijdt, J. Maertens, and E. Van Wijngaerden. 2007. Fungemia at a tertiary care hospital: incidence, therapy, and distribution and antifungal susceptibility of causative species. Eur. J. Clin. Microbiol. Infect. Dis. 26:541-547.
17. Matar, M. J., L. Ostrosky-Zeichner, V. L. Paetznick, J. R. Rodriguez, E. Chen, and J. H. Rex. 2003. Correlation between E-test, disk diffusion, and microdilution methods for antifungal susceptibility testing of fluconazole and voriconazole. Antimicrob. Agents Chemother. 47:1647-1651.
18. Morrell, M., V. J. Fraser, and M. H. Kollef. 2005. Delaying the empiric treatment of Candida bloodstream infection until positive blood culture results are obtained: a potential risk factor for hospital mortality. Antimicrob. Agents Chemother. 49:3640-3645.
19. Ostrosky-Zeichner, L., J. H. Rex, M. A. Pfaller, D. J. Diekema, B. D. Alexander, D. Andes, S. D. Brown, V. Chaturvedi, M. A. Ghannoum, C. C. Knapp, D. J. Sheehan, and T. J. Walsh. 2008. Rationale for reading fluconazole MICs at 24 hours rather than 48 hours when testing Candida spp. by the CLSI M27-A2 standard method. Antimicrob. Agents Chemother. 52:4175-4177.
20. Park, B. J., B. A. Arthington-Skaggs, R. A. Hajjeh, N. Iqbal, M. A. Ciblak, W. Lee-Yang, M. D. Hairston, M. Phelan, B. D. Plikaytis, A. N. Sofair, L. H. Harrison, S. K. Fridkin, and D. W. Warnock. 2006. Evaluation of amphotericin B interpretive breakpoints for Candida bloodstream isolates by correlation with therapeutic outcome. Antimicrob. Agents Chemother. 50:1287-1292.
21. Pfaller, M. A., and D. J. Diekema. 2007. Epidemiology of invasive candidiasis: a persistent public health problem. Clin. Microbiol. Rev. 20:133-163.
22. Pfaller, M. A., D. J. Diekema, L. Boyken, S. A. Messer, S. Tendolkar, and R. J. Hollis. 2003. Evaluation of the Etest and disk diffusion methods for determining susceptibilities of 235 bloodstream isolates of Candida glabrata to fluconazole and voriconazole. J. Clin. Microbiol. 41:1875-1880.
23. Pfaller, M. A., D. J. Diekema, L. Ostrosky-Zeichner, J. H. Rex, B. D. Alexander, D. Andes, S. D. Brown, V. Chaturvedi, M. A. Ghannoum, C. C. Knapp, D. J. Sheehan, and T. J. Walsh. 2008. Correlation of MIC with outcome for Candida species tested against caspofungin, anidulafungin, and micafungin: analysis and proposal for interpretive MIC breakpoints. J. Clin. Microbiol. 46:2620-2629.
24. Pfaller, M. A., D. J. Diekema, J. H. Rex, A. Espinel-Ingroff, E. M. Johnson, D. Andes, V. Chaturvedi, M. A. Ghannoum, F. C. Odds, M. G. Rinaldi, D. J. Sheehan, P. Troke, T. J. Walsh, and D. W. Warnock. 2006. Correlation of MIC with outcome for Candida species tested against voriconazole: analysis and proposal for interpretive breakpoints. J. Clin. Microbiol. 44:819-826.
25. Pfaller, M. A., D. J. Diekema, and D. J. Sheehan. 2006. Interpretive break-points for fluconazole and Candida revisited: a blueprint for the future of antifungal susceptibility testing. Clin. Microbiol. Rev. 19:435-447.
26. Sobel, J. D. 2006. The emergence of non-albicans Candida species as causes of invasive candidiasis and candidemia. Curr. Infect. Dis. Rep. 8:427-433.
27. Vandenbossche, I., M. Vaneechoutte, M. Vandevenne, T. De Baere, and G. Verschraegen. 2002. Susceptibility testing of fluconazole by the NCCLS broth macrodilution method, E-test, and disk diffusion for application in the routine laboratory. J. Clin. Microbiol. 40:918-921.
28. White, T., T. Bruns, S. Lee, and J. Taylor. 1990. Amplification and direct sequencing of fungal ribosomal RNA genes for phylogenetics, p. 315-322. In M. A. Innis, D. H. Gefland, J. J. Sninsky, and T. J. White (ed.), PCR protocols: a guide to methods and applications. Academic Press, San Diego, CA.
29. Zilberberg, M. D., A. F. Shorr, and M. H. Kollef. 2008. Secular trends in candidemia-related hospitalization in the United States, 2000-2005. Infect. Control Hosp. Epidemiol. 29:978-980.